London, England, United Kingdom · On-site
Your mission Engitix Therapeutics is a pioneering biotechnology company dedicated to unlocking extracellular matrix (ECM) biology to develop transformative therapeutics for fibrosis and oncology. We are seeking a motivat…
Skills: Human tissue handling, Histology, Cell-based assays, Extracellular matrix biology, Immunofluorescence
London, England, United Kingdom · On-site
Your mission Engitix Therapeutics is a London-based biotechnology company unlocking the extracellular matrix (ECM) as a source of novel therapeutic targets for fibrosis and cancer. Through our unique understanding of the…
Skills: Biospecimen management, LIMS, Sample procurement, Quality assurance, Regulatory compliance
London, England, United Kingdom · On-site
Your mission Engitix Therapeutics is a London-based biotechnology company unlocking the extracellular matrix (ECM) as a source of novel therapeutic targets for fibrosis and cancer. Our proprietary platform integrates pro…
Skills: R, Python, Bulk Transcriptomics, Single-cell Transcriptomics, Spatial Transcriptomics
London, England, United Kingdom · On-site
Your mission Engitix Therapeutics is a London-based biotechnology company unlocking the extracellular matrix (ECM) as a source of novel therapeutic targets for fibrosis and cancer. Our proprietary platform integrates pro…
Skills: Bioinformatics, Computational biology, R, Python, Transcriptomics
London, England, United Kingdom · On-site
Your mission We are seeking an accomplished Senior scientist of macrophage biology to provide scientific leadership in macrophage biology and immune-stromal interactions, driving target identification, validation and tra…
Skills: Macrophage Biology, Target Identification, Target Validation, Flow Cytometry, Immunofluorescence
London, England, United Kingdom • On-site
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
The scientist will process human tissue samples and execute complex ECM-based cell assays to support target identification and validation. They will also generate high-quality imaging data and collaborate with multidisciplinary teams to optimize drug screening platforms.
Candidates must hold a BSc or MSc in a relevant life sciences discipline with 1-3 years of laboratory experience. Essential skills include proficiency in histology, mammalian cell culture, and immunofluorescence microscopy.
Decoding the ECM space to unlock unprecedented therapies for chronic diseases
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
Offices: 21 Lombard Street, London, England EC3V 9AH, GB · Rowalnd Hill Street, London, London NW32PF, GB · 700 Main street, Cambridge, Massachusetts 02139, US
Decoding the ECM space to unlock unprecedented therapies for chronic diseases
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
Offices: 21 Lombard Street, London, England EC3V 9AH, GB · Rowalnd Hill Street, London, London NW32PF, GB · 700 Main street, Cambridge, Massachusetts 02139, US
